Trends Shaping The $10+ Billion Cold-Chain Pharma Market 2025-2030 - Integration Of Blockchain-Enabled Tracking Platforms For End-To-End Cold-Chain Visibility And Compliance Presents Opportunities

(MENAFN- GlobeNewsWire - Nasdaq) Growing demand for biologics and vaccines, coupled with sustainability initiatives and regulatory compliance, call for resilient, transparent, and collaborative supply chain solutions

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Cold-chain Pharma Market by Packaging Type (Active Packaging, Passive Packaging), Temperature Range (Controlled Ambient, Frozen, Refrigerated), Distribution Channel, Service Type, Mode, Product Type, End User - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.

The pharmaceutical cold-chain market is rapidly evolving, driven by complex regulatory frameworks, digital transformations, and mounting supply chain challenges. Senior decision-makers must navigate a landscape where operational precision, compliance, and resilience are non-negotiable for delivering sensitive therapies effectively.

Market Snapshot: Cold-Chain Pharma Market Growth and Outlook

The Cold-chain Pharma Market grew from USD 8.85 billion in 2024 to USD 10.04 billion in 2025. It is expected to continue growing at a CAGR of 12.75%, reaching USD 18.20 billion by 2030. Expansion is driven by rising global demand for biologics, advanced therapies, and vaccines requiring precise temperature-controlled logistics. The market's upward trajectory reflects the need for integrated solutions that address end-to-end visibility and compliance while minimizing operational risks.

Scope & Segmentation

This research report provides detailed segmentation and regional analysis, offering actionable market intelligence for strategic planning:

• Packaging Types: Active packaging includes refrigerated containers and temperature-controlled pallets. Passive options involve dry ice containers, gel packs, and insulated shippers.
• Temperature Ranges: Spanning controlled ambient, refrigerated shipments, as well as frozen categories such as deep frozen and ultra frozen for thermally sensitive products.
• Distribution Channels: Covers in-house operations (both centralized and decentralized models) and third-party logistics, including contract logistics and dedicated cold chain providers.
• Service Types: Storage solutions in cold warehouses and temperature-controlled containers; transportation via air, rail, road, and sea; and value-added services like kitting, repacking, and monitoring.
• Mode of Transport: Encompasses air (express, freighter), rail (dedicated cold cars, intermodal), road (full truckload, less than truckload), and sea (container ships, reefer vessels).
• Product Types: Includes biologics, diagnostics, small molecule drugs (injectable, oral), and vaccines such as live attenuated and mRNA formulations.
• End Users: Spans clinics (community, outpatient), contract research organizations, hospitals (general, specialty), and retail pharmacies (chain, independent).
• Regional Coverage: Americas (notably U.S. states, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (UK, Germany, France, plus selected MENA and African markets); Asia-Pacific (China, India, Japan, Australia, South Korea, and major Southeast Asian countries).
• Technological Innovations: Real-time sensor arrays, predictive analytics for routing, blockchain-enabled traceability, and AI-powered monitoring platforms.

Key Takeaways for Senior Decision Makers

• Technological integration, such as continuous real-time monitoring and immutable record keeping, is increasing supply chain transparency and mitigating risks for temperature excursions.
• Companies are establishing robust compliance systems and investing in adaptive packaging to align with evolving regulatory expectations for traceability and reporting.
• Supply chain models are becoming more agile, with stakeholders opting for multimodal transport solutions and regionally diversified sourcing to strengthen resilience.
• Sustainability imperatives are prompting adoption of bio-based insulating materials, energy-efficient refrigeration, and optimized route planning to reduce environmental impacts.
• Collaboration is deepening across logistics, packaging, and technology sectors to co-develop innovative solutions and streamline end-to-end pharmaceutical distribution.
• Cold-chain operators are leveraging partnership-driven models and cloud-based data platforms for unified shipment management and rapid response to operational deviations.

Tariff Impact on Pharmaceutical Cold-Chain Logistics

In 2025, new US tariffs affecting imported packaging materials and refrigeration equipment are reshaping procurement and cost structures for pharmaceutical logistics providers. Strategies such as local sourcing, modular container design, and domestic route optimization are being adopted to mitigate both financial and operational exposure. Collaborative developments between logistics partners and packaging suppliers are ensuring regulatory compliance and sustained product integrity in response to shifting trade environments.

Why This Report Matters

• Enables leaders to benchmark strategies and adopt emerging technologies for improved operational efficiency and risk management.
• Delivers in-depth segmentation and regional analysis to support data-driven decision-making, investment prioritization, and supply chain resiliency.
• Provides clarity on regulatory, technological, and geopolitical factors shaping future competitive advantage in cold-chain pharma logistics.

Conclusion

Adopting innovation, strategic collaboration, and rigorous compliance is essential for sustaining performance and supply continuity in the cold-chain pharmaceutical market. This report equips senior decision-makers with the insights needed to navigate complexity and drive results across global networks.

Key Attributes

Report Attribute	Details
No. of Pages	193
Forecast Period	2025-2030
Estimated Market Value (USD) in 2025	$10.04 Billion
Forecasted Market Value (USD) by 2030	$18.2 Billion
Compound Annual Growth Rate	12.7%
Regions Covered	Global

Key Topics Covered
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of blockchain-enabled tracking platforms for end-to-end cold-chain visibility and compliance
5.2. Adoption of IoT-enabled smart packaging solutions to monitor critical temperature deviations in real time
5.3. Scaling infrastructure for ultra-low temperature storage to support mRNA vaccine distribution at global scale
5.4. Implementation of eco-friendly biodegradable thermal insulation materials in cold-chain transport packaging
5.5. Strategic partnerships between biopharma companies and specialized 3PLs for last-mile temperature-controlled deliveries
5.6. Regulatory harmonization efforts to streamline cross-border cold-chain pharma logistics and reduce compliance delays
6. Market Insights
6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025

8. Cold-chain Pharma Market, by Packaging Type
8.1. Introduction
8.2. Active Packaging
8.2.1. Refrigerated Containers
8.2.2. Temperature-Controlled Pallets
8.3. Passive Packaging
8.3.1. Dry Ice Containers
8.3.2. Gel Packs
8.3.3. Insulated Shippers
9. Cold-chain Pharma Market, by Temperature Range
9.1. Introduction
9.2. Controlled Ambient
9.3. Frozen
9.3.1. Deep Frozen
9.3.2. Ultra Frozen
9.4. Refrigerated
10. Cold-chain Pharma Market, by Distribution Channel
10.1. Introduction
10.2. In-House
10.2.1. Centralized Distribution
10.2.2. Decentralized Distribution
10.3. Third Party Logistics
10.3.1. Contract Logistics
10.3.2. Dedicated Cold Chain Providers
11. Cold-chain Pharma Market, by Service Type
11.1. Introduction
11.2. Storage
11.2.1. Cold Storage Warehouses
11.2.2. Temperature-Controlled Containers
11.3. Transportation
11.3.1. Air Transport
11.3.2. Rail Transport
11.3.3. Road Transport
11.3.4. Sea Transport
11.4. Value Added Services
11.4.1. Kitting And Repacking
11.4.2. Monitoring Services
12. Cold-chain Pharma Market, by Mode
12.1. Introduction
12.2. Air
12.2.1. Express
12.2.2. Freighter
12.3. Rail
12.3.1. Dedicated Cold Cars
12.3.2. Intermodal
12.4. Road
12.4.1. Full Truckload
12.4.2. Less Than Truckload
12.5. Sea
12.5.1. Container Ships
12.5.2. Reefer Vessels
13. Cold-chain Pharma Market, by Product Type
13.1. Introduction
13.2. Biologics
13.2.1. Monoclonal Antibodies
13.2.2. Therapeutic Proteins
13.3. Diagnostics
13.3.1. PCR Kits
13.3.2. Rapid Test Kits
13.4. Small Molecule Drugs
13.4.1. Injectable
13.4.2. Oral
13.5. Vaccines
13.5.1. Live Attenuated
13.5.2. mRNA
14. Cold-chain Pharma Market, by End User
14.1. Introduction
14.2. Clinics
14.2.1. Community Clinics
14.2.2. Outpatient Clinics
14.3. Contract Research Organizations
14.3.1. Analytical Services
14.3.2. Clinical Trial Services
14.4. Hospitals
14.4.1. General Hospitals
14.4.2. Specialty Hospitals
14.5. Retail Pharmacies
14.5.1. Chain Pharmacies
14.5.2. Independent Pharmacies
15. Americas Cold-chain Pharma Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Cold-chain Pharma Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Cold-chain Pharma Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis

The companies profiled in this Cold-chain Pharma market report include:

• Americold Logistics LLC
• Lineage Logistics LLC
• Kuehne + Nagel International AG
• Deutsche Post AG
• DB Schenker GmbH
• United Parcel Service, Inc.
• FedEx Corporation
• DSV Panalpina A/S
• CEVA Logistics AG
• Agility Public Warehousing Company K.S.C.P

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN12082025004107003653ID1109917932